Use of the fetal reprogramming of a PPAR delta agonist

A technology of reprogramming and agonist, applied in the direction of medical preparations containing active ingredients, applications, animal feed, etc.

Inactive Publication Date: 2013-09-11
SEOUL NAT UNIV R&DB FOUND
View PDF76 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, few cases of endurance enhancement by PPARδ agonists alone are known so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of the fetal reprogramming of a PPAR delta agonist
  • Use of the fetal reprogramming of a PPAR delta agonist
  • Use of the fetal reprogramming of a PPAR delta agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0170] Mouse fetal reprogramming using PPARδ agonist

[0171] To study the role of PPARδ in fetal reprogramming during mammalian development, the inventors used a method of administering a PPARδ agonist to a pregnant mother (maternal treatment). For fetal reprogramming, at a concentration of 10 mg / kg per day ( concentration) Orally administered PPARδ agonist to pregnant mice, in figure 1 The specific experimental methods are summarized in .

[0172] (1) Confirm whether PPARδ agonists pass through the placenta

[0173]Pharmacokinetic experiments were performed to confirm whether the PPARδ agonist (CMDD1111) used in this study crossed the placenta. CMDD1111 was administered to mice on day 16 of gestation at a concentration of 10 mg / kg, after which the concentration of the compound distributed in the blood of the mother animals and fetuses was analyzed for 24 hours. As a result, the maximum plasma concentration of the compound (C max ) is 38μM, the time to reach its maximu...

Embodiment 2

[0176] Verification of the effect of slow muscle fiber increase in mice subjected to fetal reprogramming through PPARδ activation

[0177] Slow-twitch fibers have a lot of myoglobin (which is an oxygen transport protein) and therefore appear redder than fast-twitch fibers. When the skin of the fetus was removed and its muscles observed, it could be seen that the administered mouse group had redder muscles ( Figure 7 A and 7B). To confirm whether slow-twitch fiber production was increased due to the administration of the substance (CMDD1111), the hind legs of mice were excised and then frozen in OCT. The frozen muscle tissue was cut into 8 mm thick sections by using a cryostat, mounted on glass slides, after which the sections were subjected to metachromatic staining. Slow-twitch fibers are stained a darker blue than fast-twitch fibers by metachromatic staining. Such as Figure 7 C It can be confirmed that dark blue myofibers are increasingly produced in the gastrocnemius...

Embodiment 3

[0178] Verification of the increasing effect of slow muscle fibers regulated by calcium ions

[0179] The present inventors performed gene expression analysis to determine the cause of the increased slow-twitch fiber production in mice subjected to fetal reprogramming activated by PPARdelta.

[0180] (1) Gene expression analysis using microarray

[0181] Regarding the animals, the gastrocnemius muscle of 3-week-old mice fetally reprogrammed by a PPARδ agonist (CMDD1111) was excised, after which total RNA was extracted by using Trizol reagent (Gibco). The isolated RNA was subjected to a quantification and purification verification process before being used for gene expression analysis using a Mouse4302.0 (Affimatrix) chip.

[0182] In general, slow-twitch fibers have more mitochondria, increased fatty acid oxidation, and lower contraction rates than fast-twitch fibers. From the analysis results, it was confirmed that the expression of all genes related to the above three typ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a novel use of a PPAR d agonist, and more particularly, to a fetal reprogramming effect of a PPAR d agonist. According to the present invention, a PPAR d agonist adjusts calcium ion during embryo genesis and a early fetal development period to increase slow muscle fiber and to thus improve muscle endurance, thereby improving lipid and glucose metabolism and reprogramming the metabolism of the entire body, thus preventing / inhibiting the occurrence of metabolic diseases, such as obesity and diabetes in an adult body caused by a high-fat diet and a lack of exercise, and improving memory for an adult. In addition, fetal reprogramming using a PPAR d agonist prevents / inhibits the occurrence of diabetes in a mouse model for diabetes.; Therefore, the PPAR d agonist may be used in a pharmaceutical composition for enhancing the endurance of a human and an animal by embryonic / fetal reprogramming, preventing / inhibiting metabolic diseases such as obesity, diabetes, arteriosclerosis and fatty liver, and enhancing memory. The PPAR d agonist may also be used in a nutritional supplement for pregnant women, in food additives, in a functional food supplement or functional beverage composition, in pharmaceutical compositions for animals, in an endurance enhancer for animals, in dry milk and baby formula compositions, in an animal feed composition, etc.

Description

technical field [0001] The present invention relates to fetal reprogramming of PPARδ agonists ( fetal reprogramming), more specifically related to the novel use of PPARδ agonists that modulate calcium ions during embryogenesis and early fetal development to increase slow-twitch muscle fibers and thus enhance muscle endurance, thereby improving lipid and glucose metabolism As well as reprogramming the metabolism of the whole body and thus preventing / suppressing the onset of metabolic diseases such as obesity and diabetes caused by high fat diet and lack of exercise in the adult and adult body and improving memory. According to the present invention, PPARδ agonists are effective in preventing / suppressing the onset of diabetes in normal mice (even in mice with congenital diabetes) as well as in controlling fetal reprogramming, thus being effective through fetal reprogramming in humans and animals Prevention of metabolic diseases (such as obesity, diabetes, etc.) and treatment o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A61K31/426A61K31/427A61P3/04A61P3/10
CPCA23L2/02A23L2/52A61K31/41A61K31/4155A61K31/422A61K31/426A61K31/427A61K31/4439A23K20/111A23L33/10A61P1/16A61P3/04A61P3/06A61P3/10A61P9/10A61P21/00A61P25/16A61P25/28A61P43/00C07D277/26C07D293/06C07D417/06C07D421/06C07D277/30
Inventor姜宪中黄厚商陈政郁
OwnerSEOUL NAT UNIV R&DB FOUND